THOUSAND OAKS, Calif.,
Nov. 28, 2018 /PRNewswire/
-- Amgen (NASDAQ:AMGN) will host a webcast call for the
investment community at the 60th American Society of Hematology
(ASH) Annual Meeting & Exposition on Monday, Dec. 3, 2018, at 8 p.m.
PT. David M. Reese, M.D., executive vice president of Research
and Development at Amgen, together with other members of Amgen's
management team and a clinical investigator, will participate to
discuss data presented at ASH and the Company's oncology program,
including the bispecific T Cell engager
(BiTE®) immuno-oncology platform.
Live audio of the investor call will be simultaneously broadcast
over the Internet and will be available to members of the news
media, investors and the general public.
The webcast, as with other selected presentations regarding
developments in Amgen's business given by management at certain
investor and medical conferences, can be found on Amgen's website,
www.amgen.com, under Investors. Information regarding presentation
times, webcast availability and webcast links are noted on Amgen's
Investor Relations Events Calendar. The webcast will be archived
and available for replay for at least 90 days after the
event.
About Amgen
Amgen is committed to unlocking
the potential of biology for patients suffering from serious
illnesses by discovering, developing, manufacturing and delivering
innovative human therapeutics. This approach begins by using tools
like advanced human genetics to unravel the complexities of disease
and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and
leverages its expertise to strive for solutions that improve health
outcomes and dramatically improve people's lives. A biotechnology
pioneer since 1980, Amgen has grown to be one of the
world's leading independent biotechnology companies, has reached
millions of patients around the world and is developing a pipeline
of medicines with breakaway potential.
For more information, visit www.amgen.com and follow
us on www.twitter.com/amgen.
CONTACT: Amgen, Thousand
Oaks
Kristen Davis, 805-447-3008
(Media)
Kristen Neese, 805-313-8267
(Media)
Arvind Sood, 805-447-1060
(Investors)
View original content to download
multimedia:http://www.prnewswire.com/news-releases/amgen-to-webcast-investor-call-at-ash-2018-300757139.html
SOURCE Amgen